Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Trevi Therapeutics and keeping the price target at $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on several promising developments for Trevi Therapeutics. The company recently shared positive results from their Phase 2a CORAL trial, where their drug Haduvio met all secondary endpoints for treating cough in patients with idiopathic pulmonary fibrosis (IPF). This success is complemented by ongoing Phase 1 studies that are evaluating the drug’s impact on respiratory function and its interaction with standard IPF treatments, with expectations of favorable outcomes.
Furthermore, Trevi is planning to expand its clinical programs with a Phase 3 trial for IPF-related cough and a Phase 2b trial for renal cell carcinoma, both set to begin in the first half of 2026. The company is also exploring opportunities in non-IPF interstitial lung disease (ILD) cough, which could significantly broaden their market reach. With a strong cash position of $204 million, Trevi is well-funded to support these ambitious trials and initiatives, adding to the confidence in their potential for growth.
In another report released on August 8, Stifel Nicolaus also reiterated a Buy rating on the stock with a $15.00 price target.